Cargando…
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
BACKGROUND: Fatigue is a multifactorial symptom commonly reported by patients with prostate cancer as a result of disease and treatment. This study assesses the impact enzalutamide has on patient-reported fatigue (“fatigue”) by using patient-reported outcomes from four pivotal, placebo-controlled tr...
Autores principales: | Tombal, Bertrand F., Freedland, Stephen J., Armstrong, Andrew J., Beer, Tomasz M., Stenzl, Arnulf, Sternberg, Cora N., Hussain, Maha, Ganguli, Arijit, Ramaswamy, Krishnan, Bhadauria, Hemant, Ivanescu, Cristina, Turnbull, James, Holmstrom, Stefan, Saad, Fred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184276/ https://www.ncbi.nlm.nih.gov/pubmed/34518652 http://dx.doi.org/10.1038/s41391-021-00447-9 |
Ejemplares similares
-
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
por: Tombal, Bertrand, et al.
Publicado: (2021) -
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022) -
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
por: Devlin, Nancy, et al.
Publicado: (2017) -
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
por: Joshua, Anthony M., et al.
Publicado: (2022) -
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
por: Armstrong, Andrew J., et al.
Publicado: (2019)